HLNE

Hamilton Lane INC (HLNE) - 10-Q Summary

Business Context and Reporting Period

Company: Hamilton Lane Incorporated (HLNE)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025 (Second Quarter of Fiscal Year 2026)
Business Overview: A global private markets investment solutions provider offering customized separate accounts, specialized funds, and advisory services. The company operates as a holding company with its principal asset being a controlling interest in Hamilton Lane Advisors, L.L.C. (HLA).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 27.3% year-over-year (YoY) for the quarter ($190.9M vs. $150.0M) and 5.8% for the six-month period ($366.8M vs. $346.7M).
  • Management & Advisory Fees: Increased $22.3M (18.6%) for the quarter, driven by growth in specialized funds (evergreen and direct equity) and reporting/analytics subscriptions.
  • Incentive Fees: Increased $14.3M (47.4%) for the quarter, primarily due to $13.1M in performance fees from evergreen funds.
• Profitability: Net income attributable to HLI rose 28.9% YoY for the quarter ($70.9M vs. $55.0M).
  • Expenses: Total expenses increased 34.2% YoY for the quarter ($111.2M vs. $82.8M). Compensation and benefits rose $21.9M, driven by higher base compensation (headcount growth) and a $7.7M increase in equity-based compensation.
• Investment Income: Equity in income of investees surged $13.7M YoY for the quarter ($20.1M vs. $6.4M) due to larger increases in underlying investment valuations.
• Balance Sheet: Investments in consolidated funds grew significantly from $96.7M to $328.4M, reflecting increased investment activity and consolidation of new funds.

Guidance, Outlook, and Material Events

• Strategic Partnership: On November 2, 2025, the company entered a 10-year strategic partnership with The Guardian Life Insurance Company to manage their existing ~$5B private equity portfolio and future commitments (~$500M/year). The deal includes a warrant for up to 400,000 Class A shares.
• Capital Markets Activity:
  • September 2025 Offering: Completed a registered offering of 528,705 shares (150k from selling stockholder, 378k new issuance). Net proceeds of $55.5M were used to settle exchanges of HLA units.
  • Dividend: Declared a quarterly dividend of $0.54 per share for Q3 2025 (payable Jan 7, 2026).
• Debt Amendments: On October 1, 2025, the 2022 Multi-Draw Term Loan was amended to reduce the aggregate principal available to $50M and adjust interest rates to the greater of Prime - 1.35% or 3.0%.
• Asset Sale: On October 23, 2025, sold interests in a wholly-owned entity for $92.3M cash.
• Risks: Primary risks include volatility in incentive fees, reliance on non-controlling interest distributions, and potential clawbacks on carried interest. The company notes that historical fund performance is not indicative of future stock performance.

Investor Verification Checklist

• Non-GAAP Reconciliation: Verify the calculation of Fee Related Earnings (FRE) and Adjusted EBITDA, specifically the add-backs for equity-based compensation and the inclusion of Fee Related Performance Revenues (FRPR).
• Non-Controlling Interests (NCI): Review the significant portion of net income attributable to NCI ($32.7M for the quarter) and the economic ownership percentage of HLA held by HLI (77.3% as of Sept 30, 2025).
• Incentive Fee Sustainability: Assess the composition of the $44.6M in incentive fees, noting the heavy reliance on performance fees from evergreen funds which may be more volatile than management fees.
• Debt Covenants: Confirm compliance with the Consolidated Leverage Ratio (3.50:1.00) and minimum management fee covenants under the Senior Notes and Loan Agreements.
• Unfunded Commitments: Review the $269.5M in aggregate unfunded commitments to Funds and the potential impact on future cash flows.